Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
Bengaluru, Karnataka, India: March 27, 2026: Biocon Limited (BSE: 532523; NSE: BIOCON) announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026. The appointment follows approvals from the Nomination & Remuneration Committee and the Board of Directors. Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited.This leadership transition is part of the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The combined enterprise is positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies.
Executive Chairperson, Kiran Mazumdar-Shaw stated Shreehas Tambe will lead the combined platform, strengthening the company's ability to operate at scale and compete effectively in global markets. During his tenure as CEO and Managing Director of Biocon Biologics, the company achieved a valuation of USD 5.5 billion in 2025.
Siddharth Mittal will transition to another leadership role within the Biocon Group.
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said the focus will be on strengthening the foundation, consolidating the business, and accelerating sustainable growth.
About Shreehas Tambe
Shreehas Tambe joined Biocon nearly three decades ago. During his tenure as CEO and Managing Director of Biocon Biologics, the company became one of the world’s Top 5 biosimilar companies by revenue with a valuation of USD 5.5 billion in 2025. He previously served as Chief Operating Officer and Deputy CEO of Biocon Biologics, driving enterprise-wide operations and global growth.About Biocon Limited
Biocon Limited (BSE: 532523, NSE: BIOCON) provides affordable, life-changing medicines to patients worldwide. It offers biosimilars and generics across chronic and non-communicable diseases. The company has commercialized 12 biosimilar products and 30+ generic formulations globally and has a research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. Biocon operates in over 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.